Clinical Trials Logo

Clinical Trial Summary

Retrospective analysis of real-world disease outcomes in non-severe COVID-19 patients with high risk factors of progression to severe disease, including death, without definitive anti-SARS-CoV-2 treatment


Clinical Trial Description

This is a retrospective, observational, real-world study to review outcomes of Mild to Moderate COVID-19 patients admitted to Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine (hereinafter referred to as Ruijin Hospital) from March to June 2022. These patients should be with risk factors for progression to severe disease (including death) and without definitive anti-novel coronavirus (SARS-CoV-2) treatment. The database of this study will be the hospital information system (HIS) of Ruijin Hospital. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05489874
Study type Observational
Source Shanghai Vinnerna Biosciences Co., Ltd.
Contact Jie Wang, Project Manager
Phone 8618036618073
Email jie_wang5@junshipharma.com
Status Recruiting
Phase
Start date July 14, 2022
Completion date December 30, 2024